Equitar’s solutions unlock the value of health equity to achieve positive health impact from investments in healthcare and life sciences.
Health Equity Solutions for Impact
We assure and operationalize health equity for all stakeholders across the LP, GP, and portfolio organizations. Health equity is embedded across the investing cycle and stages, from sustainability frameworks through investment policies, monitoring, and reporting, and across the entire product lifecycle and care continuum, from corporate governance through quality, product definition, clin ops, and postmarket.
​
Our Health Equity Data Cloud brings knowledge to the point of action to resolve disparities in access and outcomes, and to and enable growth with full visibility, validated measures, and controls.
​
Impact investors and their LPs select Equitar because of our principal investing experience in impact, institutional, corporate, and private venture capital, our domain expertise in enterprise software for healthcare and life sciences, and our transformative solutions that seamlessly embed health equity into existing business processes and enterprise infrastructure.
Our experience in principal investing, healthcare and life sciences, and software position Equitar to deliver excellence in technology-enabled professional services.
Professionals for Sustainable Health EquitySM
Joseph Kozikowski, MD
Joe served in institutional, corporate, private, and impact venture, and he led clinical, regulatory, and corporate development. A tech founder, he delivered software solutions to hundreds of life sciences companies and medical institutions. He researched medtech at MGH-MIT, studied corporate governance at Stanford and UCLA, strategy at JWMI, finance at Harvard, regulatory at FDLI, medicine at Johns Hopkins, and engineering at Villanova.
​
Nelia Padilla, MBA
Nelia served in institutional venture, and she led major clinical and strategic initiatives. A digital health thought leader, she delivered data-driven technology solutions to leading healthcare and life sciences companies worldwide. She studied business at Yale and biology at Harvard.
​
Stuart Pollard, PhD
Stuart served in institutional and corporate venture, and he led innovative venture models of corporate co-creation and megadeals. He led strategy, corporate development, and portfolio management at leading biotechs and growth companies. He researched molecular biology at Harvard, and he studied molecular virology and biochemistry at U Reading.
​
Anne Shehab, PhD MBA
Anne served in institutional, corporate, private, and impact venture, and she led M&A and corporate development at leading multinationals and growth companies. A medtech founder, she commercialized innovative products to medical institutions worldwide. She researched cardiovascular at Texas Heart Institute, and she studied finance at Chicago, engineering at Rice, and science at U Edinborough.
Latest Insights from Equitar
Materiality is Now
ESG Insights
Health equity materiality assessments are not an afterthought for sustainable digital health portfolios.
Calling the Health Equity Data Cloud
Health Disparity Watch
COVID telemedicine disparities go exponential without real-time health equity analytics.
Mixture Models Deliver Insights
Computational Epidemiology
Contemporary approaches to data augmentation can now handle dropouts from multiple root causes.
Elucidating Unobserved Covariates
Computational Epidemiology
Gross overdispersion is not the only way that unobserved covariates degrade outcomes in large-scale inference.